2. Amyotrophic lateral sclerosis Clinical trials / Disease details
Clinical trials : 624 / Drugs : 611 - (DrugBank : 160) / Drug target genes : 172 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03707795 (ClinicalTrials.gov) | August 21, 2017 | 14/9/2017 | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Treatment of FUS-Related ALS With Betamethasone - The TRANSLATE Study | Familial Amyotrophic Lateral Sclerosis | Drug: Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | Edward Kasaraskis | NULL | Completed | 20 Years | 80 Years | All | 6 | Early Phase 1 | United States |